Company Dermata Therapeutics, Inc.

Equities

DRMA

US2498454055

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-12 pm EDT			5-day change	1st Jan Change
3.01 ^USD	-3.83%		-19.06%	-67.10%

May. 15	Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Number of employees: 8

Managers	Title	Age	Since
Gerry Proehl CEO	Chief Executive Officer	65	14-12-07
David Hale FOU	Founder	75	14-12-07
Kyri van Hoose DFI	Director of Finance/CFO	-	21-08-31
Sean Proehl IRC	Investor Relations Contact	-	21-08-31
Christopher Nardo PRN	Corporate Officer/Principal	59	15-05-31
Maria Bedoya-Toro Munera LAW	General Counsel	72	15-12-31

Members of the board	Title	Age	Since
David Hale FOU	Founder	75	14-12-07
Gerry Proehl CEO	Chief Executive Officer	65	14-12-07
Wendell Wierenga BRD	Director/Board Member	76	16-09-19
Mary Fisher BRD	Director/Board Member	62	21-07-31
Steven Mento BRD	Director/Board Member	72	21-07-31
Kathleen Scott BRD	Director/Board Member	55	21-07-31
Andrew Sandler BRD	Director/Board Member	58	21-07-31
Brittany Bradrick BRD	Director/Board Member	54	22-01-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	562,175	545,084 ( 96.96 %)	0	96.96 %

Name	Equities	%	Valuation
Proehl Investment Ventures LLC 2.726 %	12,106	2.726 %	46 427 $
Intracoastal Capital LLC 2.161 %	9,596	2.161 %	36 801 $
David Hale 0.6161 %	2,736	0.6161 %	10 493 $
Two Sigma Securities LLC 0.2997 %	1,331	0.2997 %	5 104 $
Acadian Asset Management LLC 0.2892 %	1,284	0.2892 %	4 924 $
Citadel Securities GP LLC 0.2626 %	1,166	0.2626 %	4 472 $
Gerry Proehl 0.2486 %	1,104	0.2486 %	4 234 $
Geode Capital Management LLC 0.1838 %	816	0.1838 %	3 129 $
Maria Bedoya-Toro Munera 0.1076 %	478	0.1076 %	1 833 $
Tower Research Capital LLC 0.0863 %	383	0.0863 %	1 469 $

Name	Equities	%	Valuation
Warberg Asset Management LLC -	30,000	-	240 $
Armistice Capital LLC -	20,312	-	162 $
Boothbay Fund Management LLC -	12,000	-	96 $
UBS Securities LLC -	1,485	-	12 $
BofA Securities, Inc. -	100	-	1 $

Dermata Therapeutics, Inc.

3525 Del Mar Heights Road Suite 322

92130, San Diego

http://www.dermatarx.com

address Dermata Therapeutics, Inc.(DRMA)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.01 USD

Average target price

10 USD

Spread / Average Target

+232.23%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
DERMATA THERAPEUTICS, INC.	-67.10%	1.69M
VERTEX PHARMACEUTICALS INCORPORATED	+16.93%	123B
REGENERON PHARMACEUTICALS, INC.	+17.01%	111B
BIONTECH SE	-7.23%	23.63B
ARGENX SE	+1.98%	22.58B
GENMAB A/S	-14.29%	17.26B
BEIGENE, LTD.	-6.79%	17.6B
WUXI APPTEC CO., LTD.	-37.63%	17.61B
NEUROCRINE BIOSCIENCES, INC.	+2.17%	13.55B
SAREPTA THERAPEUTICS, INC.	+24.42%	11.34B

Bio Therapeutic Drugs